SITC 2019
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T...
An anti-carcinoma monoclonal antibody (mAb) NEO-201 can also target and eliminate human immunosuppressive regulatory T...
Discovery and Development of Monoclonal Antibodies Targeting Tumor Neo-Epitopes Presented by Dr. Philip Arlen President and CEO,...
Philip M. Arlen, M.D. Summary: Target is broadly expressed in multiple solid tumors. Exhibits both ADCC and CDC...
Dr. Philip M Arlen, will be representing Precision Biologics in the PLENARY KEYNOTE SESSION, PANEL DISCUSSION:...
Abstract Title: Phase 1 with expansion cohorts in a study of NEO-201 in adults with...
First international congress of BIOIMMUNOTHERAPY OF CANCER An International multidisciplinary meeting 12-13-14 APRILE 2019 REGGIO CALABRIA ITALY Palazzo della Provincia, Sala...
Fantini M, David JM, Wong HC, Annunziata CM, Arlen PM, Tsang KY. Cancer Biother Radiopharm. 2019...
Mechanisms of action of a neoantigen-targeting antibody NEO-201 AACR Annual Meeting - March 30-April 4 2019...
The Discovery and Development of Novel Monoclonal Antibody, NEO-201 Targeting a Novel Neoantigen Philip M. Arlen,...
Clinical trial tests safety and dosing of NEO-201 antibody in patients with advanced cancer NIH 11/01/2018 Patients...